SLFN11 and neoplasm: Significantly prolonged PFS (5.7 vs. 3.6 months; p = 0.009) and OS (12.2 vs. 7.5 months; p = 0.014) were observed in patients with SLFN11-positive tumours treated with the TMZ and veliparib combination, as further discussed below.